Literature DB >> 33554133

Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study.

Stephanie J W Shoop-Worrall1,2, Kimme L Hyrich2,3, Lucy R Wedderburn4,5,6, Wendy Thomson7,3, Nophar Geifman1.   

Abstract

BACKGROUND: Juvenile idiopathic arthritis (JIA) is a heterogeneous disease, the signs and symptoms of which can be summarised with use of composite disease activity measures, including the clinical Juvenile Arthritis Disease Activity Score (cJADAS). However, clusters of children and young people might experience different global patterns in their signs and symptoms of disease, which might run in parallel or diverge over time. We aimed to identify such clusters in the 3 years after a diagnosis of JIA. The identification of these clusters would allow for a greater understanding of disease progression in JIA, including how physician-reported and patient-reported outcomes relate to each other over the JIA disease course.
METHODS: In this multicentre prospective longitudinal study, we included children and young people recruited before Jan 1, 2015, to the Childhood Arthritis Prospective Study (CAPS), a UK multicentre inception cohort. Participants without a cJADAS score were excluded. To assess groups of children and young people with similar disease patterns in active joint count, physician's global assessment, and patient or parental global evaluation, we used latent profile analysis at initial presentation to paediatric rheumatology and multivariate group-based trajectory models for the following 3 years. Optimal models were selected on the basis of a combination of model fit, clinical plausibility, and model parsimony. FINDING: Between Jan 1, 2001, and Dec 31, 2014, 1423 children and young people with JIA were recruited to CAPS, 239 of whom were excluded, resulting in a final study population of 1184 children and young people. We identified five clusters at baseline and six trajectory groups using longitudinal follow-up data. Disease course was not well predicted from clusters at baseline; however, in both cross-sectional and longitudinal analyses, substantial proportions of children and young people had high patient or parent global scores despite low or improving joint counts and physician global scores. Participants in these groups were older, and a higher proportion of them had enthesitis-related JIA and lower socioeconomic status, compared with those in other groups.
INTERPRETATION: Almost one in four children and young people with JIA in our study reported persistent, high patient or parent global scores despite having low or improving active joint counts and physician's global scores. Distinct patient subgroups defined by disease manifestation or trajectories of progression could help to better personalise health-care services and treatment plans for individuals with JIA. FUNDING: Medical Research Council, Versus Arthritis, Great Ormond Street Hospital Children's Charity, Olivia's Vision, and National Institute for Health Research.
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Entities:  

Year:  2020        PMID: 33554133      PMCID: PMC7843954          DOI: 10.1016/S2665-9913(20)30269-1

Source DB:  PubMed          Journal:  Lancet Rheumatol        ISSN: 2665-9913


  29 in total

1.  International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

Authors:  Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

Review 2.  Juvenile idiopathic arthritis.

Authors:  Angelo Ravelli; Alberto Martini
Journal:  Lancet       Date:  2007-03-03       Impact factor: 79.321

3.  Group-based trajectory modeling in clinical research.

Authors:  Daniel S Nagin; Candice L Odgers
Journal:  Annu Rev Clin Psychol       Date:  2010       Impact factor: 18.561

4.  Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation.

Authors:  E J Brewer; J Bass; J Baum; J T Cassidy; C Fink; J Jacobs; V Hanson; J E Levinson; J Schaller; J S Stillman
Journal:  Arthritis Rheum       Date:  1977-03

5.  Predicting Which Children with Juvenile Idiopathic Arthritis Will Have a Severe Disease Course: Results from the ReACCh-Out Cohort.

Authors:  Jaime Guzman; Andrew Henrey; Thomas Loughin; Roberta A Berard; Natalie J Shiff; Roman Jurencak; Susanne M Benseler; Lori B Tucker
Journal:  J Rheumatol       Date:  2016-12-15       Impact factor: 4.666

6.  Description of active joint count trajectories in juvenile idiopathic arthritis.

Authors:  Roberta A Berard; George Tomlinson; Xiuying Li; Kiem Oen; Alan M Rosenberg; Brian M Feldman; Rae S M Yeung; Claire Bombardier
Journal:  J Rheumatol       Date:  2014-10-01       Impact factor: 4.666

7.  Construct validity of ILAR and EULAR criteria in juvenile idiopathic arthritis: a population based incidence study from the Nordic countries. International League of Associations for Rheumatology. European League Against Rheumatism.

Authors:  L Berntson; A Fasth; B Andersson-Gäre; J Kristinsson; P Lahdenne; G Marhaug; S Nielsen; P Pelkonen; E Svensson
Journal:  J Rheumatol       Date:  2001-12       Impact factor: 4.666

8.  Impact of juvenile idiopathic arthritis on quality of life during transition period at the era of biotherapies.

Authors:  Julien Wipff; Laetitia Sparsa; Anne Lohse; Pierre Quartier; Andre Kahan; Chantal Job Deslandre
Journal:  Joint Bone Spine       Date:  2015-07-29       Impact factor: 4.929

9.  Prevalence and course of lower limb disease activity and walking disability over the first 5 years of juvenile idiopathic arthritis: results from the childhood arthritis prospective study.

Authors:  Gordon J Hendry; Stephanie J Shoop-Worrall; Jody L Riskowski; Pamela Andrews; Eileen Baildam; Alice Chieng; Joyce Davidson; Yiannis Ioannou; Flora McErlane; Lucy R Wedderburn; Kimme Hyrich; Wendy Thomson; Martijn Steultjens
Journal:  Rheumatol Adv Pract       Date:  2018-11-24

10.  Long-Term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis: The Importance of Definition.

Authors:  Stephanie J W Shoop-Worrall; Suzanne M M Verstappen; Janet E McDonagh; Eileen Baildam; Alice Chieng; Joyce Davidson; Helen Foster; Yiannis Ioannou; Flora McErlane; Lucy R Wedderburn; W Thomson; Kimme L Hyrich
Journal:  Arthritis Rheumatol       Date:  2018-07-22       Impact factor: 10.995

View more
  7 in total

Review 1.  Juvenile idiopathic arthritis.

Authors:  Alberto Martini; Daniel J Lovell; Salvatore Albani; Hermine I Brunner; Kimme L Hyrich; Susan D Thompson; Nicolino Ruperto
Journal:  Nat Rev Dis Primers       Date:  2022-01-27       Impact factor: 65.038

2.  The role of APOE in cognitive trajectories and motor decline in Parkinson's disease.

Authors:  Sungyang Jo; Seon-Ok Kim; Kye Won Park; Seung Hyun Lee; Yun Su Hwang; Sun Ju Chung
Journal:  Sci Rep       Date:  2021-04-09       Impact factor: 4.379

3.  Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis.

Authors:  Luiza R Grazziotin; Gillian Currie; Marinka Twilt; Maarten J IJzerman; Michelle M A Kip; Hendrik Koffijberg; Gouke Bonsel; Susanne M Benseler; Joost F Swart; Sebastiaan J Vastert; Nico M Wulffraat; Rae S M Yeung; Wineke Armbrust; J Merlijn van den Berg; Deborah A Marshall
Journal:  Pediatr Rheumatol Online J       Date:  2022-07-23       Impact factor: 3.413

4.  Latent classes of early response trajectories to biologics initiation in juvenile idiopathic arthritis: an analysis of four trials.

Authors:  Lily Siok Hoon Lim; Shamsia Shobhan; Armend Lokku; Sarah Ringold; Eleanor Pullenayegum
Journal:  Pediatr Rheumatol Online J       Date:  2022-07-30       Impact factor: 3.413

Review 5.  Treat to Target (Drug-Free) Inactive Disease in JIA: To What Extent Is This Possible?

Authors:  Athimalaipet V Ramanan; Anne M Sage
Journal:  J Clin Med       Date:  2022-09-26       Impact factor: 4.964

6.  No evidence that genetic predictors of susceptibility predict changes in core outcomes in JIA.

Authors:  Annie Yarwood; Stephanie Shoop-Worrall; Elena López-Isac; Samantha Louise Smith; Andrew P Morris; John David Bowes; Melissa Tordoff; Kimme L Hyrich; Wendy Thomson; Stephen Eyre
Journal:  Rheumatology (Oxford)       Date:  2022-10-06       Impact factor: 7.046

7.  Nothing about us without us: involving patient collaborators for machine learning applications in rheumatology.

Authors:  Stephanie J W Shoop-Worrall; Katherine Cresswell; Imogen Bolger; Beth Dillon; Kimme L Hyrich; Nophar Geifman
Journal:  Ann Rheum Dis       Date:  2021-07-05       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.